Search
Archexin
go.drugbank.com/drugs/DB05971InvestigationalSynonyms: 5'-DG-DC-T-DG-DC-DA-T-DG-DA-T-DC-T-DC-DC-T-T-DG-DG-DC-DG-3', 5'-DG-DC-T-DG-DC-DA-T-DG-DA-T-DC-T-DC-DC-T-T-DG-DG-DC-DG-3', SODIUM PHOSPHOTHIOATEXEN-D0101
go.drugbank.com/drugs/DB06020ExperimentalXEN-D0101 is an investigational drug developed by Xention Inc. for the treatment of Atrial Fibrillation. XEN-D0101 works by being a selective antagonist of the voltage-gated potassium channel Kv1.5.
Categories: Heterocyclic Compounds, 1-RingINNO-305
go.drugbank.com/drugs/DB06025InvestigationalThe vaccine is a polyvalent Wilms tumor gene 1 (WT1) peptide analog vaccine. … INNO-305 is an investigational vaccine developed by Innovive Pharmaceuticals for the treatment of patients with acute myeloid leukemia in complete remission.
Synonyms: WT-1 analog peptide vaccinePR-15
go.drugbank.com/drugs/DB06037InvestigationalPR-15 is a novel anti-platelet protein with the potential to treat arterial thrombosis occurring during acute coronary syndromes without the bleeding risk associated with existing agents.
Trofinetide
go.drugbank.com/drugs/DB06045Approved1 (IGF-1). … Trofinetide is a novel synthetic analog of [glypromate], also known as glycine–proline–glutamate (GPE), a naturally occurring protein in the brain and the N-terminal tripeptide of insulin-like growth factor
Categories: MATE 1 Inhibitors, MATE 2 InhibitorsSynonyms: glycyl-L-2-methylprolyl-L-glutamic acidIPH 2101
go.drugbank.com/drugs/DB06049InvestigationalIPH-2101 (NN-1975), a fully human monoclonal antibody developed for patients with acute myeloid leukemia.
POT-4
go.drugbank.com/drugs/DB06056InvestigationalPOT-4 is a peptide that specifically inhibits complement activation and is initially being developed for the treatment of age-related macular degeneration (AMD). … The investigational drug was under investigation in clinical trial NCT00473928 (Safety of Intravitreal POT-4 Therapy for Patients With Neovascular Age-Related Macular Degeneration (AMD) (ASaP)).
EVT 302
go.drugbank.com/drugs/DB06057InvestigationalEVT 302 is an orally active, potent, highly selective and reversible inhibitor of MAO-B. It is in the development for smoking cessation, and potential for disease modification in Alzheimer's disease.
Categories: Heterocyclic Compounds, 1-RingXTL-6865
go.drugbank.com/drugs/DB06058InvestigationalXTL-6865 is a combination of two fully human monoclonal antibodies (Ab68 and Ab65) against the hepatitis C virus E2 envelope protein. … It is being developed to prevent HCV re-infection following a liver transplant and for the treatment of chronic HCV disease.